Skip to main content
OpenTrials
Completed

NCT Number: NCT02723032

Validation of a Miniature SpO2 Sensor in Healthy Subjects and Patients With Long-term Oxygen Therapy.

By integrating a miniaturized pulse oximetry sensor into the frame of oxygen delivery glasses which dissimulates the nasal cannula, the investigators hope to optimize and long term oxygen therapy (LTOT) regarding medical and social aspects. The validation of the novel SpO2 sensor is the first step in the concept of personalized, dynamic delivery of oxygen by eyeglasses using a closed-loop system.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Pulmonary Medicine, University Hospital Bern

Bern, Canton of Bern, 3010, Switzerland

About this study

Objectives:

  • To determine accuracy of SpO2 measurements by the novel sensor compared to 2 reference pulse oximeters in healthy subjects undergoing a normobaric hypoxic challenge provoking SpO2 desaturation.
  • To determine accuracy of SpO2 measurements by the novel sensor compared to 2 reference pulse oximeters and to arterial blood gas analysis in patients qualifying for LTOT, breathing room air at rest (lying, sitting, standing position) and during exercise (slow walking, 6-MWT, ergometer cycle).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Healthy volunteers

Inclusion criteria

  • Age 18 - 60 years,
  • Non smoker,
  • Good general health and physical fitness
  • Informed Consent

Exclusion criteria

  • Current or history of tobacco smoking (> 5 py)
  • Current alcohol or drug abuse
  • Heart disease or untreated arterial hypertension
  • Pulmonary disease
  • Epilepsy or other major neurologic disease
  • Dark skin colour
  • Known anemia
  • Severe metabolic disease (e.g. diabetes)
  • Pregnancy

Patients

Inclusion criteria

  • Age ≥ 18 years
  • Long term oxygen therapy at rest and/or on physical effort
  • Hypoxemia in arterial blood gas analysis at rest PaO2 ≤ 55 mmHg or < 60 mmHg with PHT or polycythemia (men Hb > 174 g/L, women Hb > 140 g/L) or:

Oxygen desaturation on effort (SpO2 < 90%)

  • Pulmonary disease including Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease and Sarcoidosis
  • Informed Consent

Exclusion criteria

  • Severe hypoxemia (pO2 <40 mmHg)
  • Severe hypercapnia (pCO2 >55 mmHg)
  • Acute respiratory infection or systemic infection,
  • Severe systolic heart disease (LVEF < 25%)
  • Myocardial infarction during the last month before inclusion
  • Unstable angina pectoris
  • Severe aortic stenosis (mean gradient > 40mmHg, valve area <1 cm2)
  • Rhythmogenic heart disease
  • Severe or untreated arterial hypertension (blood pressure > 180mmHg systolic, >100mmHg diastolic)
  • Anemia (Hb < 120 g/l)
  • Known or suspected coagulation disorder (e.g. INR > 4)
  • Severe or untreated metabolic disorder
  • Neurologic disease or dementia
  • Pregnancy
  • History of non-compliance to medical treatment
  • Current alcohol, drug abuse or current tobacco smoking
  • Dark skin color

Treatment and study plan

OxyFrame

Device

Validation of a miniaturized pulse oximetry sensor for integration into the frame of oxygen delivery glasses.

Primary outcomes

  1. Assessment of accuracy in patients

    Time frame: At baseline

    Assessment of the accuracy of the novel pulse oximeter sensor in patients qualifying for LTOT over the entire saturation range by calculating accuracy root mean square (ARMS). Continuous SpO2 measurement of the novel pulse oximeter will be compared to measurements assessed by 2 standard pulse oximeters and arterial blood gas analysis.

Secondary outcomes

  1. Assessment of accuracy in healthy volunteers

    Time frame: At baseline

    Assessment of accuracy of the novel pulse oximeter sensor in healthy subjects undergoing a normobaric hypoxic challenge provoking SpO2 desaturation. SpO2 will be measured continuously over the hole procedure and SpO2 range by the novel pulse oximeter sensor and the 2 reference pulse oximeters.

Sponsors and collaborators

Lead sponsor

Insel Gruppe AG, University Hospital Bern

Other

Registry information

Official study title

Validation of a Miniature SpO2 Sensor in Healthy Subjects and Patients With Long-term Oxygen Therapy. A Prospective, Method Comparison, Proof of Concept Study.

Acronym: OxyFrame

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Mar 30, 2016
Registry last updated
Oct 27, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.